• Zai Lab recently reported that the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (Zoci), for treating neuroendocrine carcinomas, a group of aggressive cancers with limited options.
• This second orphan designation, following a similar decision in Europe, underlines Zoci’s potential as a first-in-class therapy in a difficult tumor type.
• We’ll now examine how this new Orphan Drug Designation for Zoci could influence Zai Lab’s investment narrative and long-term pipeline potential.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Zai Lab Investment Narrative Recap

To own Zai Lab, you need to believe its mix of partnered assets and emerging proprietary programs can eventually turn growing revenue into sustainable profitability, despite ongoing losses and competition in China. The new U.S. Orphan Drug Designation for Zoci supports the long term pipeline story in difficult cancers, but it does not materially change the near term catalyst around upcoming earnings or the key risk of high costs against still negative net income.

Among recent announcements, the April 2026 AACR data for Zoci and the start of a global Phase 3 trial are most relevant. Together with the new U.S. and earlier European orphan designations, they frame Zoci as a central pipeline asset that could, if development progresses successfully, become an important driver in Zai Lab’s oncology portfolio and a focal point for future data readouts and regulatory milestones.

Yet alongside this opportunity, you should be aware that...

Zai Lab's narrative projects $832.0 million revenue and $157.9 million earnings by 2029. This requires 22.4% yearly revenue growth and a $336.0 million earnings increase from -$178.1 million today.

Uncover how Zai Lab's forecasts yield a $33.30 fair value, a 80% upside to its current price.

Exploring Other Perspectives

Some of the lowest forecast analysts painted a far more cautious picture, assuming revenue of about US$712,100,000 and earnings near US$105,000,000 by 2029, so you should weigh this more pessimistic view against the new Zoci designations and your own expectations before deciding how much optimism is reasonable.

Explore 4 other fair value estimates on Zai Lab - why the stock might be worth over 4x more than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Zai Lab research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Zai Lab research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zai Lab's overall financial health at a glance.

Ready For A Different Approach?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.